Obesity, dopamine and the metabolic syndrome: Potential of dopaminergic agents in the control of metabolism

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 2, 2006, Pages 179-184

  Pijl, Hanno ^a   Romijn, Johannes A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dopamine; Dopamine (D2) receptor; Hypertension; Metabolic syndrome; Obesity

Indexed keywords

BROMOCRIPTINE; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUCOSE; INSULIN; LIPID; QUINAGOLIDE; SULFONYLUREA DERIVATIVE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DISEASE MODEL; DIZZINESS; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; ENERGY EXPENDITURE; FOOD INTAKE; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RELEASE; LIPID METABOLISM; LOCOMOTION; METABOLIC REGULATION; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOLOGY; PROLACTINOMA; PROTEIN FUNCTION; RECEPTOR DENSITY; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

EID: 33646047761     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000216967.74622.9c     Document Type: Review

References (63)

1. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428. An excellent overview of the metabolic syndrome and its clinical ramifications.
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403.
3. Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365:1333-1346. This study provides a concise summary of current treatment options for type 2 diabetes.
4. Pijl H, Meinders AE. Modulation of monoaminergic neural circuits: potential for the treatment of type 2 diabetes mellitus. Treatment Endocrinol 2002; 1:71-78.
5. Neve KA, Seamans JK, Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004; 24:165-205.
6. Bonci A, Hopf FW. The dopamine D2 receptor: new surprises from an old friend. Neuron 2005; 47:335-338.
7. Missale C, Nash SR, Robinson SW, et al. Dopamine receptors: from structure to function. Physiol Rev 1998; 78:189-225.
8. Rubi B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta-cells and mediate inhibition of insulin secretion. J Biol Chem 2005; 280:36824-36832. This paper opens up a new area of research on the role of dopaminergic signals in the control of metabolism. The presence of dopamine D2 receptors in pancreatic beta cells had not been described before.
9. Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic. Cell 1995; 83:1197-1209.
10. Fetissov SO, Meguid MM, Chen C, et al. Synchronized release of dopamine and serotonin in the medial and lateral hypothalamus of rats. Neuroscience 2000; 101:657-663.
11. Small DM, Jones-Gotman M, Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. Neuroimage 2003; 19:1709-1715.
12. Cannon CM, Abdallah L, Tecott LH, et al. Dysregulation of striatal dopamine signaling by amphetamine inhibits feeding by hungry mice. Neuron 2004; 44:509-520. This paper highlights the role of dopamine as a satiety signal, offers novel ideas on the role of dopamine in appetite control, and includes an excellent review of the literature.
13. Baik JH, Picetti R, Saiardi A, et al. Parkinsonian-like locomotor impairment in mice lacking dopamine D2 receptors. Nature 1995; 377:424-428.
14. Tataranni PA, Baier L, Jenkinson C, et al. A Ser311Cys mutation in the human dopamine receptor D2 gene is associated with reduced energy expenditure. Diabetes 2001; 50:901-904.
15. Cincotta AH, Tozzo E, Scislowski PW. Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice. Life Sci 1997; 61:951-956.
16. Scislowski PW, Tozzo E, Zhang Y, et al. Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists. Int J Obes Relat Metab Disord 1999; 23:425-431.
17. Levine JA, Lanningham-Foster LM, McCrady SK, et al. Interindividual variation in posture allocation: possible role in human obesity. Science 2005; 307:584-586. A provocative paper suggesting that 'non-exercise activity thermogenesis' contributes significantly to obesity in humans and that non-exercise activity thermogenesis is genetically determined. It is tempting to postulate that dopaminergic neurotransmission may be involved.
18. Levine JA, Eberhardt NL, Jensen MD. Role of nonexercise activity thermogenesis in resistance to fat gain in humans. Science 1999; 283:212-214.
19. Filozof C, Gonzalez C. Predictors of weight gain: the biological-behavioural debate. Obes Rev 2000; 1:21-26.
20. Meier AH, Cincotta AH. Circadian rhythms regulate the expression of the thrifty genotype/phenotype. Diabetes Rev 1997; 4:464-487.
21. Pijl H. Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome? Eur J Pharmacol 2003; 480:125-131.
22. Schwartz MW, Porte D Jr. Diabetes, obesity, and the brain. Science 2005; 307:375-379. An excellent overview of current perceptions pertaining to the role of neural circuits in the brain in the pathogenesis of obesity and diabetes mellitus.
23. Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. Science 2005; 307:1909-1914.
24. Stanley S, Wynne K, McGowan B, et al. Hormonal regulation of food intake. Physiol Rev 2005; 85:1131-1158.
25. Li S, Pelletier G. The role of dopamine in the control of neuropeptide Y neurons in the rat arcuate nucleus. Neurosci Lett 1986; 69:74-77.
26. van den Hoek AM, Voshol PJ, Karnekamp BN, et al. Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin. Diabetes 2004; 53:2529-2534.
27. Brandi LS, Santoro D, Natali A, et al. Insulin resistance of stress - sites and mechanisms. Clin Sci 1993; 85:525-535.
28. Jose PA, Eisner GM, Felder RA. Dopaminergic mechanisms in the development of hypertension. In: McCarty R, Blizard DA, Chevalier RI, editors. Development of the hypertensive phenotype: basic and clinical studies. Amsterdam: Elsevier Science; 1999. pp. 1-44.
29. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 1998; 32:187-197.
30. Hussain T, Lokhandwala MF. Renal dopamine receptors and hypertension. Exp Biol Med (Maywood) 2003; 228:134-142.
31. Sibley DR. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu Rev Pharmacol Toxicol 1999; 39:313-341.
32. Nagahama S, Chen YF, Lindheimer MD, et al. Mechanism of the depressor action of LY171555, a selective dopamine D2 receptor agonist, in the anesthetized rat. J Pharmacol Exp Ther 1986; 239:426-432.
33. Li XX, Bek M, Asico LD, et al. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension 2001; 38:303-308.
34. Parker SG, Raval P, Yeulet S, et al. Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist. Eur J Pharmacol 1994; 265:17-26.
35. Degli EE, Sturani A, Santoro A, et al. Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Clin Sci (Lond) 1985; 69:51-56.
36. Goldberg LI. Dopamine receptors and hypertension. Physiologic and pharmacologic implications. Am J Med 1984; 77:37-44.
37. Rahmouni K, Correia ML, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005; 45:9-14.
38. Wofford MR, Hall JE. Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004; 10:3621-3637.
39. Ahren B. Autonomic regulation of islet hormone secretion - implications for health and disease. Diabetologia 2000; 43:393-410.
40. Ericson LE, Hakanson R, Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia 1977; 13:117-124.
41. Rosati G, Maioli M, Aiello I, et al. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease. Eur Neurol 1976; 14:229-239.
42. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005; 66:504-514.
43. Levin BE, Dunn-Meynell AA. Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet-induced obese rats. Am J Physiol 1997; 272:R1365-R1370.
44. Chang S, Graham B, Yakubu F, et al. Metabolic differences between obesity-prone and obesity-resistant rats. Am J Physiol 1990; 259:R1103-R1110.
45. Levin BE, Finnegan M, Triscari J, et al. Brown adipose and metabolic features of chronic diet-induced obesity. Am J Physiol 1985; 248:R717-R723.
46. Orosco M, Rouch C, Meile MJ, et al. Spontaneous feeding-related monoamine changes in rostromedial hypothalamus of the obese Zucker rat: a microdialysis study. Physiol Behav 1995; 57:1103-1106.
47. Orosco M, Trouvin JH, Cohen Y, et al. Ontogeny of brain monoamines in lean and obese female Zucker rats. Physiol Behav 1986; 36:853-856.
48. Levin BE, Sullivan AC. Catecholamine levels in discrete brain nuclei of seven month old genetically obese rats. Pharmacol Biochem Behav 1979; 11:77-82.
49. Fetissov SO, Meguid MM, Sato T, et al. Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake. Am J Physiol Regul Integr Comp Physiol 2002; 283:R905-R910.
50. Ster AM, Kowalski TJ, Dube MG, et al. Decreased hypothalamic concentration of neuropeptide Y correlates with onset of hyperphagia in fa/fa rats on postnatal day 12. Physiol Behav 2003; 78:517-520.
51. White BD, Martin RJ. Evidence for a central mechanism of obesity in the Zucker rat: role of neuropeptide Y and leptin. Proc Soc Exp Biol Med 1997; 214:222-232.
52. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet 2001; 357:354-357.
53. Kok P, Roelfsema F, Frolich M, et al. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab 2004; 89:4445-4449. This study provides indirect evidence of a link between dopamine D2 receptor deficiency in the brain and (visceral) obesity in humans.
54. Epstein LH, Jaroni JL, Paluch RA, et al. Dopamine transporter genotype as a risk factor for obesity in African-American smokers. Obes Res 2002; 10:1232-1240.
55. Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002; 147:77-84.
56. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol (Oxf) 1998; 48:547-553.
57. Barnett PS, Palazidou E, Miell JP, et al. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502. Q J Med 1991; 81:891-906.
58. Di Chiara G, Porceddu ML, Vargiu L, et al. Stimulation of "regulatory" dopamine receptors by bromocriptine (CB-154). Pharmacology 1978; 16 (Suppl. 1):135-142.
59. Kok P, Roelfsema F, Frolich M, et al. Short term bromocriptine treatment improves diurnal glucose metabolism and enhances energy expenditure in obese premenopausal women [abstract]. ADA Annual Sessions Abstract Book 2005; 1843-P.
60. Aminorroaya A, Janghorbani M, Ramezani M, et al. Does bromocriptine improve glycemic control of obese type-2 diabetics? Horm Res 2004; 62:55-59. This study corroborates the theory that dopamine D2 agonistic drugs beneficially impact on glycemic control in obese humans with type 2 diabetes.
61. Volkow ND, Wang GJ, Maynard L, et al. Brain dopamine is associated with eating behaviors in humans. Int J Eat Disord 2003; 33:136-142.
62. Carr KD, Tsimberg Y, Berman Y, et al. Evidence of increased dopamine receptor signaling in food-restricted rats. Neuroscience 2003; 119:1157-1167.
63. Ingram DK, Chefer S, Matochik J, et al. Aging and caloric restriction in nonhuman primates: behavioral and in vivo brain imaging studies. Ann NY Acad Sci 2001; 928:316-326.